CSIMarket
 
Senseonics Holdings Inc   (SENS)
Other Ticker:  
 
 
Price: $0.7020 $-0.03 -3.836%
Day's High: $0.75 Week Perf: 3.39 %
Day's Low: $ 0.70 30 Day Perf: 34.61 %
Volume (M): 3,030 52 Wk High: $ 1.05
Volume (M$): $ 2,127 52 Wk Avg: $0.66
Open: $0.73 52 Wk Low: $0.46



 Market Capitalization (Millions $) 416
 Shares Outstanding (Millions) 592
 Employees 89
 Revenues (TTM) (Millions $) 19
 Net Income (TTM) (Millions $) -32
 Cash Flow (TTM) (Millions $) 20
 Capital Exp. (TTM) (Millions $) 0

Senseonics Holdings Inc
We are a medical technology firm focusing on the research and production of glucose monitoring solutions with distinctive, long-term implanted glucose management technologies to change lives in the worldwide diabetic community. Our Eversense, Eversense XL, and Eversense E3 continuous glucose monitoring (CGM) systems are designed to continuously and accurately measure glucose levels in people with diabetes using an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for up to six months, versus seven to 14 days for non-implantable CGM systems.
We believe that Eversense provides a more convenient method of CGM by providing longer duration, superior accuracy, wireless communication, on-body vibratory alerts, gentle-on-the-skin adhesive patch, data sharing capability, and a removable smart transmitter. We affixed the CE mark to the original Eversense CGM system in June 2016, which marked the first certification for the product to be sold within the European Economic Area, or EEA. Subsequently, we affixed the CE mark to the extended life Eversense XL CGM system in September 2017 which is currently available in select markets in Europe and the Middle East. In June 2018, the U.S. Food and Drug Administration, or FDA, approved the Eversense CGM system. In June 2019, we received FDA approval for the non-adjunctive indication (dosing claim) for the Eversense system. With this approval and the availability of a new app in December 2019, the Eversense system can now be used as a therapeutic CGM in the United States to replace fingerstick blood glucose measurement to make treatment decisions, including insulin dosing.
As with any new product, the success of the commercial launch of the Eversense E3 product in the U.S. will be subject to significant uncertainty and risks, and will require time to ramp up. Key areas of strategic focus in the U.S. commercial launch of the six month product where performance will impact the success of the launch will be: (1) growing the installed base of users, (2) increasing patient awareness of Eversense above current levels in order to expand the population of Eversense users, through driving sales and marketing efforts on the Eversense E3 system, (3) increasing awareness and adoption of Eversense by healthcare providers, including high volume CGM prescribers, through expanded targeted marketing efforts, (4) educating patients and prescribers regarding the six-month product and its benefits relative to the 90-day product, (5) continuing to grow the base of the authorized inserters through geographically targeted efforts so that potential users locating a qualified inserter of Eversense is not an impediment to adoption, (6) timely establishing and maintaining favorable payor coverage for the product, including transitioning commercial payors from 90-day coverage to six month coverage, and (7) Ascensia's continued organizational development of its U.S. sales and marketing capabilities relative to CGM.


   Company Address: 20451 Seneca Meadows Parkway Germantown 20876 MD
   Company Phone Number: 515-7260   Stock Exchange / Ticker: NYSEAMER SENS
   SENS is expected to report next financial results on March 14, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABT        1.34% 
DXCM   -1.44%    
MOVE        5.54% 
• View Complete Report
   



Senseonics Holdings Inc

Explosive Growth: Senseonics Holdings Inc Reveals Game-Changing Top-line Progress, Surpassing Expectations in Recent Quarter

Senseonics Holdings Inc, a leading player in the Electronic Instruments & Controls industry, has shown remarkable resilience and prosperity in the third quarter of 2023. While many companies in the same sector are grappling with receding businesses and facing diminishing revenue, Senseonics Holdings Inc has managed to outperform its peers.
In the financial period ending September 30, 2023, Senseonics Holdings Inc witnessed a substantial 11.9% increase in revenue compared to the previous year, reaching an impressive $5.17 million. This growth demonstrates the company's strong ability to adapt and thrive in a challenging market.

Senseonics Holdings Inc

Senseonics Holdings Inc Surpasses Expectations with Remarkable Revenue Growth Amid Q2 2023 Earnings Season

Senseonics Holdings Inc, a leading company in the Electronic Instruments & Controls industry, recently reported an increase in revenue of 11.093% from the same quarter a year ago to $4.13 million in the April to June 30, 2023. However, despite the revenue growth, the company experienced a shortfall per share at $-0.04, indicating a decline in profitability.
A closer look at the earnings from the prior quarter reveals a slight decrease in revenue by -0.266% from $4.14 million and a significant decline from $0.00 per share. This dip in revenue may raise concerns among investors, but the company's overall performance reflects solid efficiency and astonishing improvements from clients.

Senseonics Holdings Inc

Sensational Rise: SENS Reports an Astonishing 66.747% Surge in Revenue during Q1 2023

Senseonics Holdings Inc. has released its financial results for the January to March 31, 2023 period, showing an improvement in revenue but a significant decline in net profits. The revenue grew by 66.747% from the comparable period a year prior to $4.14 million, while sequentially revenue fell by -25.754% from $5.57 million. However, Senseonics Holdings Inc. reached 0 of $0.00 per share compared to $-0.03 a year prior and from $0.02 per share from the prior reporting period.
Despite the dip in net profit, Senseonics Holdings Inc. has been shifting its focus on improving sales, which resulted in a net margin of 32% in the current reporting period. This shift in focus is a positive sign for investors as it indicates the company's willingness to make changes to improve its financial performance.






 

Senseonics Holdings Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com